Urinary fibrin split products in lupus nephritis.
Antigen-antibody interaction and fibrin deposition at the glomerular basement membrane can release activators that ultimately convert fibrin into degradation products of varying molecular size. Thus, increased urinary fibrinogen/fibrin split products (FSP) might be expected in active lupus nephritis. A longitudinal study was done on 27 patients with biopsy-proven lupus nephritis. Those patients who were persistent FSP excretors were found to be at a significantly greater risk of progressive nephritis and renal death than those who were FSP negative. It is suggested that FSP excretion in lupus nephritis, particularly on a continued basis and despite normalization of other renal disease parameters, is a grave prognostic sign.
D000936:Antigen-Antibody Complex; D005338:Fibrin Fibrinogen Degradation Products / Q000652:urine*; D005342:Fibrinolysis; D005921:Glomerulonephritis / Q000652:urine; D016030:Kidney Transplantation; D008180:Lupus Erythematosus, Systemic / Q000652:urine*; D009393:Nephritis / Q000652:urine*; D009404:Nephrotic Syndrome / Q000652:urine; D011379:Prognosis; D012216:Rheumatic Diseases / Q000652:urine; D014184:Transplantation, Homologous
D000936:Antigen-Antibody Complex; D005338:Fibrin Fibrinogen Degradation Products